Israel Englander’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.6M | Buy |
81,196
+40,343
| +99% | +$20.7M | 0.02% | 983 |
|
|
2026
Q1 | $21.4M | Buy |
40,853
+33,875
| +485% | +$16.2M | 0.01% | 1493 |
|
|
2025
Q4 | $4.06M | Buy |
6,978
+5,180
| +288% | +$2.65M | ﹤0.01% | 3240 |
|
|
2025
Q3 | $825K | Sell |
1,798
-9,037
| -83% | -$3.37M | ﹤0.01% | 4763 |
|
|
2025
Q2 | $3.28M | Buy |
10,835
+8,328
| +332% | +$2.48M | ﹤0.01% | 3412 |
|
|
2025
Q1 | $830K | Buy |
2,507
+1,193
| +91% | +$392K | ﹤0.01% | 4490 |
|
|
2024
Q4 | $405K | Sell |
1,314
-7,616
| -85% | -$2.14M | ﹤0.01% | 4891 |
|
|
2024
Q3 | $1.9M | Buy |
+8,930
| New | +$2.28M | ﹤0.01% | 3749 |
|
|
2024
Q2 | – | Sell |
-5,653
| Closed | -$1.35M | – | 6280 |
|
|
2024
Q1 | $1.51M | Buy |
+5,653
| New | +$1.33M | ﹤0.01% | 3968 |
|
|
2023
Q4 | – | Sell |
-25,857
| Closed | -$4.52M | – | 6350 |
|
|
2023
Q3 | $3.78M | Sell |
25,857
-2,153
| -8% | -$405K | ﹤0.01% | 2977 |
|
|
2023
Q2 | $6.47M | Sell |
28,010
-92,277
| -77% | -$25M | ﹤0.01% | 2418 |
|
|
2023
Q1 | $29.1M | Buy |
+120,287
| New | +$32.8M | 0.02% | 1060 |
|
|
2022
Q4 | – | Sell |
-11,738
| Closed | -$1.15M | – | 6842 |
|
|
2022
Q3 | $763K | Buy |
11,738
+7,357
| +168% | +$511K | ﹤0.01% | 4571 |
|
|
2022
Q2 | $314K | Buy |
+4,381
| New | +$322K | ﹤0.01% | 5319 |
|
|
2022
Q1 | – | Sell |
-15,782
| Closed | -$1.34M | – | 7244 |
|
|
2021
Q4 | $1.34M | Sell |
15,782
-8,237
| -34% | -$677K | ﹤0.01% | 4133 |
|
|
2021
Q3 | $1.92M | Sell |
24,019
-21,864
| -48% | -$1.89M | ﹤0.01% | 3980 |
|
|
2021
Q2 | $4.47M | Buy |
45,883
+39,484
| +617% | +$4.67M | ﹤0.01% | 2903 |
|
|
2021
Q1 | $748K | Buy |
+6,399
| New | +$746K | ﹤0.01% | 4477 |
|
|
2020
Q4 | – | Sell |
-4,434
| Closed | -$526 | – | 5439 |
|
|
2020
Q3 | $526 | Sell |
4,434
-36,341
| -89% | -$3.95M | ﹤0.01% | 3555 |
|
|
2020
Q2 | $4.62M | Sell |
40,775
-9,972
| -20% | -$981K | 0.01% | 1838 |
|
|
2020
Q1 | $3.39M | Buy |
+50,747
| New | +$4.23M | 0.01% | 1634 |
|
|
2019
Q4 | – | Sell |
-18,960
| Closed | -$1.63M | – | 4474 |
|
|
2019
Q3 | $1.63M | Buy |
18,960
+6,729
| +55% | +$631K | ﹤0.01% | 2574 |
|
|
2019
Q2 | $1.28M | Buy |
12,231
+7,120
| +139% | +$763K | ﹤0.01% | 2654 |
|
|
2019
Q1 | $640K | Sell |
5,111
-20,167
| -80% | -$2.51M | ﹤0.01% | 3116 |
|
|
2018
Q4 | $2.85M | Buy |
+25,278
| New | +$3.91M | ﹤0.01% | 1984 |
|
|
2018
Q3 | – | Sell |
-46,505
| Closed | -$11.7M | – | 4130 |
|
|
2018
Q2 | $13M | Sell |
46,505
-45,786
| -50% | -$8.04M | 0.02% | 1145 |
|
|
2018
Q1 | $10.8M | Buy |
92,291
+88,386
| +2,263% | +$10.9M | 0.01% | 1279 |
|
|
2017
Q4 | $358K | Buy |
+3,905
| New | +$223K | ﹤0.01% | 3252 |
|
|
2017
Q2 | – | Sell |
-31,571
| Closed | -$486K | – | 3689 |
|
|
2017
Q1 | $486K | Buy |
+31,571
| New | +$497K | ﹤0.01% | 2828 |
|
|
2016
Q4 | – | Sell |
-16,202
| Closed | -$205K | – | 3556 |
|
|
2016
Q3 | $205K | Sell |
16,202
-6,384
| -28% | -$61.9K | ﹤0.01% | 2978 |
|
|
2016
Q2 | $206K | Buy |
22,586
+14,013
| +163% | +$168K | ﹤0.01% | 2893 |
|
|
2016
Q1 | $72K | Sell |
8,573
-4,916
| -36% | -$41.1K | ﹤0.01% | 3123 |
|
|
2015
Q4 | $166K | Buy |
13,489
+9,109
| +208% | +$250K | ﹤0.01% | 3159 |
|
|
2015
Q3 | $267K | Sell |
4,380
-3,681
| -46% | -$266K | ﹤0.01% | 2977 |
|
|
2015
Q2 | $629K | Sell |
8,061
-1,562
| -16% | -$131K | ﹤0.01% | 2514 |
|
|
2015
Q1 | $653K | Sell |
9,623
-10,877
| -53% | -$933K | ﹤0.01% | 2587 |
|
|
2014
Q4 | $1.9M | Buy |
20,500
+14,118
| +221% | +$1.46M | ﹤0.01% | 2018 |
|
|
2014
Q3 | $672K | Buy |
6,382
+1,969
| +45% | +$274K | ﹤0.01% | 2559 |
|
|
2014
Q2 | $632K | Buy |
+4,413
| New | +$645K | ﹤0.01% | 2458 |
|
|
2013
Q3 | – | Sell |
-963
| Closed | -$168K | – | 3472 |
|
|
2013
Q2 | $168K | Buy |
+963
| New | +$251K | ﹤0.01% | 2797 |
|
Other funds holding MDGL
BBA
RI
JT
ACA
PC
Israel Englander's MDGL Position: Q2 2026 in Review
Israel Englander increased its Madrigal Pharmaceuticals (MDGL) stake by 99% in Q2 2026, buying an estimated $20.7M and bringing the position to 81,196 shares worth $43.6M. The position accounts for 0.02% of the portfolio, ranked #983.
Israel Englander first reported a position in MDGL in Q2 2013 and has held it in 40 quarters since. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- Israel Englander held 81,196 shares of Madrigal Pharmaceuticals worth $43.6M as of Q2 2026.
- Israel Englander bought 40,343 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $20.7M.
- Madrigal Pharmaceuticals made up 0.02% of Israel Englander's portfolio in Q2 2026, its #983 holding.
- Israel Englander first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.